Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 ...
Emerging therapies such as CAR-T cell therapy and bispecific antibodies (BsAbs) have demonstrated encouraging outcomes; however, their clinical utility is guarded by toxicity profile. This systematic review and meta-analysis aims to compare the adverse event profile of CAR-T therapy and BsAbs in ...
Review Article Open access Published: 08 February 2024 Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas Asaad Trabolsi, Artavazd Arumov & Jonathan H. Schatz Blood Cancer Journal volume 14, Article number: 27 (2024) Cite this article 22k Accesses 27 ...
Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remissi
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BC
are in either preclinical or clinical evaluation. In this Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting strategies, clinical applications, and adverse events. We also discuss novel alternative bispecific ...
Though T-cell redirecting therapies have shown excellent efficacy in advanced multiple myeloma, the ability of these therapies to overcome high-risk disease such as extramedullary involvement in myeloma is an area of critical attention. In this review, we seek to examine the specific impact of ...
EP: 7.Referral Process: CAR T-Cell Therapy EP: 8.CAR T: Impact of Recent Approvals on the Referral Process EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM Video co...
One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.Precision therapy with targeted agents against tyrosine kinases ...
T cells for tumour cell kill with chimeric antigenic T-cell (CAR T-cell) therapy and bispecific antibodies have become important therapeutic options in relapsed multiple myeloma. Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target ...